Skip to main content

Advertisement

ADVERTISEMENT

News

News
03/30/2022
Access to gender-affirming medical interventions was associated with 60% lower odds of depression and 73% lower odds of self-harm or suicidal thoughts in transgender and nonbinary youths (TNB) over 1 year.
Access to gender-affirming medical interventions was associated with 60% lower odds of depression and 73% lower odds of self-harm or suicidal thoughts in transgender and nonbinary youths (TNB) over 1 year.
Access to gender-affirming...
03/30/2022
Psych Congress Network
News
03/29/2022
The Social Attention and Communication Surveillance–Revised (SACS-R) tool combined with the SACS-Preschool (SACS-PR) tool (SACS-R+PR) is highly accurate in detecting early autism.
The Social Attention and Communication Surveillance–Revised (SACS-R) tool combined with the SACS-Preschool (SACS-PR) tool (SACS-R+PR) is highly accurate in detecting early autism.
The Social Attention and...
03/29/2022
Psych Congress Network
News
03/25/2022
Children and teenagers who sustain a concussion are at increased risk of mental health issues, psychiatric hospitalization, and self-harm, suggest new study findings.
Children and teenagers who sustain a concussion are at increased risk of mental health issues, psychiatric hospitalization, and self-harm, suggest new study findings.
Children and teenagers who...
03/25/2022
Neurology

Advertisement

News
03/23/2022
The early phase of the COVID-19 pandemic was associated with excess mortality in older adults with Alzheimer disease and related dementias (ADRD) in the United States—particularly among those who identified as Asian, Black, or Hispanic.
The early phase of the COVID-19 pandemic was associated with excess mortality in older adults with Alzheimer disease and related dementias (ADRD) in the United States—particularly among those who identified as Asian, Black, or Hispanic.
The early phase of the COVID-19...
03/23/2022
Neurology
News
03/23/2022
Results of a new study released by Wesana Health show that administration of an antidepressant 3 weeks after a psilocybin loading dose provided a 39% improvement in depressive behaviors.
Results of a new study released by Wesana Health show that administration of an antidepressant 3 weeks after a psilocybin loading dose provided a 39% improvement in depressive behaviors.
Results of a new study released...
03/23/2022
Psych Congress Network
News
03/22/2022
Two experts involved in the research and development of digital tools to support clinical care recently discussed how their offerings will contribute to mental health practice.
Two experts involved in the research and development of digital tools to support clinical care recently discussed how their offerings will contribute to mental health practice.
Two experts involved in the...
03/22/2022
Psychiatry & Behavioral Health

Advertisement

News
03/21/2022
Recent study finds workplace physical activity program reported feeling less anxious, stressed, and depressed, and said they felt more alert during the day and slept better at night.
Recent study finds workplace physical activity program reported feeling less anxious, stressed, and depressed, and said they felt more alert during the day and slept better at night.
Recent study finds workplace...
03/21/2022
Psych Congress Network
News
03/21/2022
The revised DSM-5-TR includes updates and clarifying modifications to the criteria sets for more than 70 disorders, updates to the descriptive text, and also examines the impact of racism and discrimination.
The revised DSM-5-TR includes updates and clarifying modifications to the criteria sets for more than 70 disorders, updates to the descriptive text, and also examines the impact of racism and discrimination.
The revised DSM-5-TR includes...
03/21/2022
Psych Congress Network
News
03/21/2022
The US Food and Drug Administration has approved Adlarity® (donepezil transdermal system) for release in the fall of 2022. Adlarity is indicated in the treatment of adults with Alzeheimer-type mild to severe dementia symptoms. Adlarity is...
The US Food and Drug Administration has approved Adlarity® (donepezil transdermal system) for release in the fall of 2022. Adlarity is indicated in the treatment of adults with Alzeheimer-type mild to severe dementia symptoms. Adlarity is...
The US Food and Drug...
03/21/2022
Psych Congress Network

Advertisement

News
03/18/2022
Older age, male sex, and having Medicaid or Medicare Advantage coverage are among patient risk factors for experiencing an opioid overdose after an initial opioid prescription, according to a study published in JAMA Network Open. “In the...
Older age, male sex, and having Medicaid or Medicare Advantage coverage are among patient risk factors for experiencing an opioid overdose after an initial opioid prescription, according to a study published in JAMA Network Open. “In the...
Older age, male sex, and having...
03/18/2022
Addiction Professional

Advertisement